Sabitlenmiş Tweet
Dr. Neil Paulvin
5.9K posts
Dr. Neil Paulvin
@NeilpDo
Longevity Physician|Hormones|| Precision Medicine Using Medicine 3.0 to help patients improve their health and optimize performance
New York, NY Katılım Temmuz 2012
4.3K Takip Edilen2.9K Takipçiler
Being a doctor is no longer core
An autist equipped with a frontier LLM and some mid lab capabilities can outperform you
English
This Friday we're cohosting an invite-only Claude Code Workshop for enterprise leaders with @AnthropicAI in NYC.
The guest list is insane. Small selection:
- CEO of JP Morgan Wealth Management
- Chief Advertising Officer of NY Times
- Head of AI Transformation at Salesforce
- Head of Data at Starwood Capital
- Head of Innovation at San Antonio Spurs
- AI Lead at PGA Tour
It's a 5-hour intensive for Fortune 500 leaders to learn how to harness the power of Claude Code through building real applications with Claude Code.
We currently have 2 spots left for the event.
If you are an enterprise leader & want to be considered, sign-up below.
If you know an enterprise leader & think they'd love this, have them sign-up below.
English
@ernestdove Stearns was 1 for 3 . He will get so paid after this. I hope Stearns tries to sign him early
English
We need more compounding pharmacies. Who should I meet?
English
@BaseballAmerica @WexlerRules @BrewersPD @Brewers @nashvillesounds @BiloxiShuckers So maybe Brewers player development and drafting not Stearns’ ability
English
Brewers player development is at it again.
@BrewersPD now has TWO more Top 100 Prospects after today's update.
Risers, fallers & new additions: baseballamerica.com/stories/risers…
English
Don't like this psych meds should not be runner stamped the goal is to come off. Too many side effects
Healthcare AI Guy@HealthcareAIGuy
NEW: AI is now prescribing psychiatric meds Legion Health, a YC-backed AI-native telepsychiatry clinic, is launching the first mental health program where AI can handle prescription renewals, starting in Utah Patients pay $20/month and expansion to other states is planned
English
Dr. Neil Paulvin retweetledi
New study has strengthened link between infectious mono and Multiple Sclerosis. By analyzing 2 decades of health records, researchers found people who contracted mono as teenagers or adults were 3x more likely to develop MS later vs those who didn’t
neurology.org/doi/10.1212/WN…
English
The crackdown is here they are going after gray market peptides and Glp-1
Sheel Mohnot@pitdesi
The peptide crackdown is real. They (FDA?) got Amazon to take down bacteriostatic water (what people use to mix peptides) I just bought some last week, there were 20+ options when I bought, now there aren't any.
English
Dr. Neil Paulvin retweetledi
Whoop has made a lot of athletes money. You know that a whoop athlete has a good agent / manager because they enabled their athlete to invest. Many athletes miss out on great equity deals because their agents are just incentivized to get 10%+ of cash being paid to the athlete and thus block deals and investments when that’s not the case.
Kurt Badenhausen@kbadenhausen
2017: Kevin Durant invests in Whoop 2018: Whoop valued at $125M 2020: KD invests in Whoop again 2026: Whoop valued at $10.1B KD has not sold any of his stake. Value up 81x since his first investment in the tech wearable brand. sportico.com/personalities/… via @sportico
English
Minor leaguers recently released by the Mets:
Trey McGough
Robinson Martinez
Jose Aular
Nick Roselli
Zebulon Vermillion
English
Mets minor leaguers placed on the 7-day IL:
RHP Josh Blum
RHP Calvin Ziegler
OF Estarling Mercado
INF Jeremy Rodriguez
LHP Daviel Hurtado
Austin Brown, Jace Hampson and Wilson Lopez to 60-day IL.
English
Dr. Neil Paulvin retweetledi
BREAKING: OpenEvidence is expanding into insurance authorizations
After launching medical coding last week, it’s now moving into prior auth and prescriptions via a partnership with Tandem
The race to become the all-in-one health AI platform is officially on
English
@statto @sciencefocus Amazing how you avoided the peptides that are FDA approved thus having research which are many. Using ghk-cu for skin has many studies. Explain the situation with bpc that the patent holder does not want to spend the millions of dollars to do the studies.
English
I spoke with BBC @sciencefocus about peptides:
“I am shocked by how bad the evidence is,” says Dr Andrew Steele, director of The Longevity Initiative, “I thought it was going to be shaky, but there is just absolutely nothing here.” sciencefocus.com/the-human-body…
English
I will be presenting on Urolithin A and Osteoarthritis next week! I’d love to have you tune in! @4f2a9ea4-e014-4389-9ac5-7a060d837a29?utm_source=Klaviyo&utm_medium=email&utm_campaign=Webinar%20Invite%3A%20Mitochondria%20and%20Osteoarthritis&utm_id=01KN587FGMPF96G35JS80K2F6G&tw_profile_id=01JTNHKFFDS29CP74HXZJ1KJ3P&tw_medium=campaign&_kx=B3B7c1YAAhbztmiDvfg2D0vZNgpnaUGTuClgiCA2FCckr6hkkedvRNFm8FI8nAQ2.Y8q6aT" target="_blank" rel="nofollow noopener">events.teams.microsoft.com/event/0cf788db…
English
@OkaneInfinite It should not be given to patients with medullary cancer which is on Glp-1’s and some studies show it may decrease cancer risk
English
@NeilpDo Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.
English
Foundayo has many benefits lower cost, oral, good weight loss benefits, no specific diet and water rules like oral semaglutide. Still no cardiac data and other benefits with injections sleep apnea, fatty liver etc.
Matthew Herper@matthewherper
Eli Lilly’s obesity pill approved by FDA, setting up competition with Novo Nordisk statnews.com/2026/04/01/eli…
English
Dr. Neil Paulvin retweetledi
98% of all drugs can't reach your brain. The blood-brain barrier blocks them.
It's the single biggest obstacle in treating neurological disease. Alzheimer's, Parkinson's, brain cancer. Most
therapies never get where they need to go.
On March 25, the @US_FDA approved the first biologic ever engineered to cross it.
Avlayah, built by @Denalitx, treats Hunter syndrome. It fuses an enzyme to a transferrin receptor-binding domain that hijacks the brain's own iron supply route. The protein latches onto receptors on the barrier and rides through.
Clinical result: 91% reduction in brain disease markers. 93% of patients (41 out of 44) reached levels seen in healthy people by week 24.
This isn't just a rare disease win. It's proof that large molecules can be engineered to breach the wall.
If this transport platform generalizes, Alzheimer's, Parkinson's, ALS, and brain cancers all become druggable.
The first door through the wall is open.
English
Dr. Neil Paulvin retweetledi
AI Captures 55% of Health Tech Funding.
AI-focused companies now dominate venture capital in healthcare. In 2025, AI captured 55% of all health tech funding—up from just 29% in 2022.
Our money is on @khealth
English
Irresponsible that @EricTopol blocks comment on post with misleading info. Approximately one third of the peptides that will be in the list are FDA approved so are tested. Others like ghk-cu have human studies and are commonly used in many products. This is for the cream which is the better product anyway
English
Noom, @wearehims, @superpower and other major companies buying compounding pharmacies getting ready for the peptide announcement.
1, This will lower prices for those who just want the basics.
2 . May not provide good doctor support for those who want or need more nuance.
Those interested need to figure what they want from where they buy peptides.
Hims House@himshouse
$HIMS $LLY $NVO 🚨 BREAKING: Noom is acquiring a 503A pharmacy to prepare for the peptide boom We sat down with @GeoffCook (Noom CEO) to discuss why vertical integration is so important, how large the peptide market is going to be, and the evolving dynamics between telehealth platforms and big pharma A great episode with one of the best CEOs in the game - thanks again, Geoff! 00:00 - Why pharma needs DTC platforms 03:03 - Noom's 90% revenue growth 05:01 - Why Noom bought Tailor Made Compounding 07:29 - The case for vertical integration 08:56 - Compounded GLP-1s aren't going anywhere 16:48 - The Hims-Novo deal 19:08 - Noom's pitch to next-gen pharma 24:24 - Peptide market sizing 25:33 - Why GLP-1 users will buy peptides first 27:22 - Ten million potential peptide patients 👀 30:09 - When will legalization happen? 31:09 - Tracking the FDA green list 34:26 - Who wins when peptides go legal? 37:58 - Why Noom won't rush peptide launch 39:33 - Geoff's BPC-157 ski injury recovery 46:42 - Expanding at-home labs past 30 biomarkers 52:47 - Noom IPO coming?! Not financial, legal, or medical advice
English